4.7 Article

Mitochondria-targeted nanoplatforms for enhanced photodynamic therapy against hypoxia tumor

Journal

JOURNAL OF NANOBIOTECHNOLOGY
Volume 19, Issue 1, Pages -

Publisher

BMC
DOI: 10.1186/s12951-021-01196-6

Keywords

Hypoxic tumor; 3-Bromopyruvate; Respiration inhibition; Photodynamic therapy; Nanomedicine

Funding

  1. National Natural Science Foundation of China [81801711, 81801717]
  2. Key Project of Chongqing Natural Science Foundation [cstc2019jcyj-zdxmX0019]
  3. Key Project of Application Development Plan of Chongqing [cstc2019jscx-dxwtBX0004]
  4. Joint Project of Chongqing Municipal Science and Technology Bureau Health Committee [2021MSXM259]

Ask authors/readers for more resources

This study demonstrated a multistage nanoplatform encapsulating photosensitizer and oxygen regulator to achieve precise cancer therapy and imaging guidance. The nanoplatform penetrated deep into tumors, remained in mitochondria, and efficiently enhanced ROS generation, making tumor cells more susceptible to PDT.
Background Photodynamic therapy (PDT) is a promising therapeutic modality that can convert oxygen into cytotoxic reactive oxygen species (ROS) via photosensitizers to halt tumor growth. However, hypoxia and the unsatisfactory accumulation of photosensitizers in tumors severely diminish the therapeutic effect of PDT. In this study, a multistage nanoplatform is demonstrated to overcome these limitations by encapsulating photosensitizer IR780 and oxygen regulator 3-bromopyruvate (3BP) in poly (lactic-co-glycolic acid) (PLGA) nanocarriers. Results The as-synthesized nanoplatforms penetrated deeply into the interior region of tumors and preferentially remained in mitochondria due to the intrinsic characteristics of IR780. Meanwhile, 3BP could efficiently suppress oxygen consumption of tumor cells by inhibiting mitochondrial respiratory chain to further improve the generation of ROS. Furthermore, 3BP could abolish the excessive glycolytic capacity of tumor cells and lead to the collapse of ATP production, rendering tumor cells more susceptible to PDT. Successful tumor inhibition in animal models confirmed the therapeutic precision and efficiency. In addition, these nanoplatforms could act as fluorescence (FL) and photoacoustic (PA) imaging contrast agents, effectuating imaging-guided cancer treatment. Conclusions This study provides an ideal strategy for cancer therapy by concurrent oxygen consumption reduction, oxygen-augmented PDT, energy supply reduction, mitochondria-targeted/deep-penetrated nanoplatforms and PA/FL dual-modal imaging guidance/monitoring. It is expected that such strategy will provide a promising alternative to maximize the performance of PDT in preclinical/clinical cancer treatment.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available